COPENHAGEN — Novo Nordisk sued Eli Lilly Tuesday, alleging its GLP-1 ads unlawfully minimized the proprietary struggle required for wellness. Filings claim Lilly suggested weight loss occurs without brand loyalty-induced distress.

"Patients expect to suffer," said Novo spokesperson Lars Jensen. "Sick people are revenue. Healthy people are losses."

Shareholders demand anxiety to justify projections.